Meet Angela Graves, our Senior Director of Trial Informatics and Training, who's exemplifying what it means to #SolveOn. She founded “Together We Can Change,” a nonprofit serving weekly meals to individuals facing homelessness, demonstrating her unwavering commitment to her community. Angela's passion for helping others inspires us all on #TeamIncyte, and we couldn't be prouder of the difference she's making. Learn more about her impact. #SolveOn https://bit.ly/3zWyNJt
About us
Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity. Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia. We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list. For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.
- Website
-
http://www.incyte.com
External link for Incyte
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Wilmington, Delaware
- Type
- Public Company
- Specialties
- Oncology, Immuno-oncology, Targeted Therapy, Immunology, and Inflammation
Locations
-
Primary
1801 Augustine Cut-Off
Wilmington, Delaware 19803, US
Employees at Incyte
-
Harry Atkins
Senior Director, Alliance Management, Global Strategy and Corporate Development at Incyte
-
Dana Walters
Medical Regulatory Writer
-
Steven Flostrand
Executive Director, Value, Access & Pricing (Europe) at Incyte
-
Onofrio Mastandrea
Regional Vice President, General Manager | Board Member | Forbes Top 100 Managers 2023
Updates
-
The application deadline is almost here! Submit an innovative idea for the Incyte Ingenuity Awards in Vitiligo™ before time runs out. https://bit.ly/3ZPimte
Apply to the Incyte Ingenuity Awards in Vitiligo™
-
We’ve welcomed Lee Heeson to #TeamIncyte. Lee joins as Executive Vice President and Head of Incyte International bringing more than 25 years of global, commercialization experience. Most recently, Lee was Executive Vice President, Commercial International at Seagen.
-
How much do you know about atopic dermatitis? This #NationalEczemaAwarenessMonth, learn more about the most common form of eczema, which affects 10% of adults globally. https://bit.ly/3NceniE
-
Incyte has been named to Newsweek’s list of America’s 100 Most Loved Workplaces for another year! We’re so proud of our team’s commitment to innovation centered around patient care. #SolveOn https://bit.ly/3XNJm9K
-
We are committed to advancing science for patients, regardless of the size of the patient population. Hear from patients diagnosed with cholangiocarcinoma (CCA), a rare cancer that forms in the bile ducts, to understand what inspires us to #SolveOn. #RareCancerDay https://bit.ly/3Y1oJs7
Rare Cancer Day 2024
-
#News: Data from our dermatology portfolio will be presented at the 2024 European Academy of Dermatology and Venereology Congress. Read our latest press release to learn more about data at #EADV2024. https://bit.ly/3ZxPdCE
-
Representing 10% of leukemia cases, chronic myeloid leukemia (CML) continues to affect many lives around the world. Learn about the significant impact of CML. #WorldCMLDay #SolveOnForBloodCancer #BloodCancerAwarenessMonth https://bit.ly/3MUlmNm
World CML Day 2024
-
It was an incredible experience connecting with brilliant minds at the ESMO - European Society for Medical Oncology Congress in Barcelona, Spain. #ESMO24
-
We’re pleased to share that positive data from the Phase 2 AGAVE-201 study in patients with chronic graft-versus-host disease (#GVHD), in partnership with Syndax Pharmaceuticals, was published in NEJM Group. Read more. https://bit.ly/3XLu5aL
Affiliated pages
Similar pages
Browse jobs
Stock
INCY
NASDAQ
20 minutes delay
$66.03
-1.46 (-2.163%)
- Open
- 67.36
- Low
- 65.88
- High
- 67.465
Data from Refinitiv
See more info on